3D Eye Solutions, Inc. (OTCMKTS:TDEY) Rushes Up

After the spike 3D Eye Solutions, Inc. (OTCMKTS:TDEY)’s stock had in the end of February, as it gained a whopping 263% in value on a massive volume, things kind of got out of control and by Tuesday this week the gains were obliterated as TDEY stood at $0.001 per share.

The press release with which the company announced that a new CEO with quite a lot of experience has been appointed didn’t manage to stop TDEY from having red sessions, but yesterday we saw some positive movement.

The company informed the public that they have purchased a proprietary software package from ProTek Capital, Inc. (OTCMKTS:PRPM) called MaryGen for 50 thousand shares of preferred TDEY stock and with it they will be able to provide for the enterprise resource planning (ERP) needs of companies in the medical marijuana sector.

Interestingly enough, the company fails to mention the ticker symbol of the other party in the transaction. Maybe this is because PRPM is a company in which TDEY‘s Chariman, Edward Vakser is also Chairman in. Also, it is quite interesting that TDEY has decided to have something to do with the medical marijuana sector, considering the recent hype and all the shells that suddenly decided to brach out in the cannabis business.

Further suspicion should be raised after looking at comments on investor message boards that suggest and point out reasons that TDEY might be a scam. What is even more disturbing, however, is an attachment in one of the posts that shows Mr. Vasker has been convicted for “breach of contract, fraud, fraudulent inducement, fraud by misrepresentation, unjust enrichment and breach of fiduciary” alongside with 2 associates of his.

It wouldn’t take a wild imagination for anyone to think that these shares might end up getting dumped in the market for profit of the insiders, but the structure of the preferred stock used for the transaction aren’t mentioned in the PR, which leaves us guessing.

In any case, the red flags for TDEY are a lot and it would be best to do your due diligence before deciding if it’s worth the risk.